close
Fox News Flash top headlines are here. Check out what’s clicking on Foxnews.com.
A Japanese health ministry panel on Monday recommended approval of the Alzheimer’s disease treatment Leqembi, following standard approval for the drug granted by U.S. regulators last month.
REVANCE’S BOTOX RIVAL GETS FDA APPROVAL FOR PAINFUL NECK MUSCLE CONDITION
The expert panel’s decision sets the stage for official approval of the drug, co-developed by Japan’s Eisai and U.S.-based Biogen.
Dr. Seth Gale points out evidence of Alzheimer’s disease on PET scans at the Center for Alzheimer Research and Treatment (CART) at Brigham and Women’s Hospital in Boston, Massachusetts, on March 30, 2023. (REUTERS/Brian Snyder/File Photo)
An Eisai executive said this month the company expects to begin marketing Leqembi in Japan within about 60 days of receiving insurance reimbursement approval from the country’s national health system.
CLICK HERE TO GET THE FOX NEWS APP
A Los Angeles-based aerospace startup called Inversion Space has unveiled Arc, its first flagship spacecraft…
Sometimes, data breaches result in more than just free credit monitoring. Recently, Facebook began paying…
Navigation apps have become an essential part of modern life. Whether you are commuting to…
Construction robots are no longer a far-off idea. They're already changing job sites by tackling…
We spend so much time online that how we connect to the internet has become…
Shoplifting has long been a challenge for retailers, but a U.S. company now believes that…